February 22, 2025 – Hyderabad-based pharmaceutical giant Granules India has made a strategic move into the Contract Development and Manufacturing Organization (CDMO) sector with the acquisition of Swiss firm Senn Chemicals AG. This acquisition, valued at CHF 20 million (approximately ₹192.5 crore), positions Granules India to expand its footprint in the growing peptide-based therapeutics market.
A Strategic Acquisition
The acquisition of Senn Chemicals AG provides Granules India with advanced capabilities in both Liquid-Phase and Solid-Phase Peptide Synthesis. Senn Chemicals has a well-established presence in pharmaceuticals, cosmetics, amino acid derivatives, and theragnostic applications, making it a valuable addition to Granules’ portfolio.
Speaking on the acquisition, Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, said, “The acquisition of Senn Chemicals AG marks a significant milestone in our strategic growth journey. By entering the peptide therapeutics segment and acquiring CDMO capabilities, we are advancing into next-generation therapeutics that align with our commitment to innovation and affordability.”
Strengthening Peptide-Based Therapeutics
With this acquisition, Granules India aims to establish itself in the fast-growing peptide-based therapeutics industry, particularly targeting anti-diabetic and anti-obesity treatments, including GLP-1 receptor agonists. Peptide therapeutics have seen a surge in demand due to their effectiveness in treating metabolic disorders, and Granules is well-positioned to capitalize on this trend.
A Promising Future
Rico Wiedenbruch, Chairman of Senn Chemicals AG, expressed enthusiasm for the partnership, highlighting Granules’ operational efficiency and global reach as key factors that will accelerate Senn’s growth. “This collaboration is a strategic fit, and we look forward to expanding our capabilities under Granules’ leadership,” he said.
Granules India’s expansion into the CDMO space underscores its commitment to diversification and innovation in specialized therapeutics. By leveraging Senn Chemicals’ established expertise, the company aims to solidify its market presence and drive future growth in the peptide-based pharmaceutical sector.
As the pharmaceutical landscape continues to evolve, Granules India’s foray into CDMO and peptide-based therapeutics marks a significant step toward its long-term vision of becoming a global leader in next-generation healthcare solutions.
